Doc code: IDS Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-09)
Approved for use through 03/31/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | Application Number | | 10575040 | |
|---|--------------------------|----|----------------|--|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Filing Date | | 2006-12-06 | |
| | First Named Inventor Noz | | lozulak et al. | |
| | Art Unit | | 1625 | |
| | Examiner Name Chang | | ang, Celia C. | |
| | Attorney Docket Numb | er | VAND-0030-US | |

| U.S.PATENTS | | | | | | | | | | |
|--------------------------|------------|---|--------------------------------|--|--------------------|---------------------|--|--|---|----|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue D |)ate | of cited Document | | Relev | s,Columns,Lines where vant Passages or Relev es Appear | |
| | 1 | 5158952 | | 1992-10 | -27 | Janssen et al. | | | | |
| | 2 | 4804663 | | 1989-02 | 2-14 Kennis et al. | | | | | |
| | 3 | 5364866 | | 1994-11 | -15 | Strupczewski et al. | | | | |
| If you wisl | h to ac | dd additional U.S. Pater | nt citatio | n inform | ation pl | ease click the | Add button. | | | |
| | | | U.S.P | ATENT | APPLIC | CATION PUBL | LICATIONS | | | |
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | 1 Publication Name of Patentee of Applicant Polyant Passages | | | | s,Columns,Lines where vant Passages or Relev es Appear | | |
| | 1 | 20040204401 | A1 | 2004-10 | -14 | Migaly | | | | |
| If you wisl | h to ac | dd additional U.S. Publi | shed Ap | plication | citation | n information p | lease click the Add | d butto | n. | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | |
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² i | | | Publication Date | Name of Patentee Applicant of cited Document | | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | T5 |
| | 1 | 402644 | EP B1 | | 1995-08-16 | Strupczewski et al. | | | | |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

| Application Number | | 10575040 | | |
|----------------------------|------|--------------|--|--|
| Filing Date | | 2006-12-06 | | |
| First Named Inventor Nozul | | ak et al. | | |
| Art Unit | | 1625 | | |
| Examiner Name | Chan | g, Celia C. | | |
| Attorney Docket Number | | VAND-0030-US | | |

| 2 | H03-63263 | JP | А | 1991-03-19 | Hoechst-Roussel Pharma | | |
|---|--|--|--|---|---|---|---|
| 3 | H09-511215 | JP | А | 1997-11-11 | Hoechst-Marion-Roussel Pharma | | |
| h to ac | dd additional Foreign Pa | atent Document | citation | information pl | ease click the Add buttor | า | |
| | | NON-PATE | NT LITE | RATURE DO | CUMENTS | | |
| Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | | | | | | | T 5 |
| 1 | STRUPCZEWSKI, J.T. et al. "3-(Arylozy) Alkylpiperidinyl-1,2-Benziosoxazoles as D2/5-HT2 Antagonists with Potential Atypical Antipsychotic Activity: Antipsychotic Profile of Iloperidone (HP 873), Journal of Medicinal Chemistry, Vol. 38, No. 7, pp. 1119-1131, 1995 | | | | | | |
| 2 | SUBRAMANIAN, N. et al., "Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone," Progress in Neuro-Psychopharmacology & Biological Psychiatry, 26:553-560, 2002 | | | | | | |
| 3 | 64 USPQ2d 1032 DECIDED 8/2002 | | | | | | |
| 4 | COREY E. J. et al., "A Stable and Easily Prepared Catalyst for the Enantioselective Reduction of Ketones. Applications to Multistep Syntheses", Journal of the American Chemical Society, Vol. 109, No. 25, pp. 7925-7926, 1987 | | | | | | |
| 5 | MUTLIB, A.E. et al., "Application of Liquid Chromatography/Mass Spectrometry in Accelerating the Identification of Human Liver Cytochrome P450 Isoforms Involved in the Metabolism of Iloperidone", The Journal of Pharmacology and Experimental Theraputics, Vol. 286, No. 3 pp. 1285-1293. | | | | | | |
| 6 | MUTLIB, A.E. et al., "Picogram determination of iloperidone in human plasma by solid-phase extraction and by high-performance liquid chromatography-selected-ion monitoring electrospray mass spectrometry", Journal of Chromatography B. 669, 1995, pp. 237-246 | | | | | | |
| 7 | MELTZER, H., "The Role of Serotonin an Antipsychotic Drug Action", Neuropsyhopharmacology, Vol. 21, No. 2S, 1999 | | | | | | |
| | 3 h to ac Cite No 1 2 3 | 3 H09-511215 h to add additional Foreign Paragraphic Cite No Include name of the a (book, magazine, jour publisher, city and/or of the Atypical Antipsychotic A | h to add additional Foreign Patent Document NON-PATEI Cite No Include name of the author (in CAPIT/ (book, magazine, journal, serial, symp publisher, city and/or country where publisher, city an | 1 Include name of the author (in CAPITAL LET (book, magazine, journal, serial, symposium, publisher, city and/or country where publisher Atypical Antipsychotic Activity: Antipsychotic Profil No. 7, pp. 1119-1131, 1995 2 SUBRAMANIAN, N. et al., "Receptor profile of P88 iloperidone," Progress in Neuro-Psychopharmacol iloperidone," Progress in Neuro-Psychopharmacol Applications to Multistep Syntheses", Journal of th 1987 5 MUTLIB, A.E. et al., "Application of Liquid Chroma Human Liver Cytochrome P450 Isoforms Involved Experimental Theraputics, Vol. 286, No. 3 pp. 128 MUTLIB, A.E. et al., "Picogram determination of iloperformance liquid chromatography-selected-ion in Chromatography B. 669, 1995, pp. 237-246 | 3 H09-511215 JP A 1997-11-11 h to add additional Foreign Patent Document citation information pl NON-PATENT LITERATURE DO Include name of the author (in CAPITAL LETTERS), title of (book, magazine, journal, serial, symposium, catalog, etc), opublisher, city and/or country where published. STRUPCZEWSKI, J.T. et al. "3-(Arylozy) Alkylpiperidinyl-1,2-Benz Atypical Antipsychotic Activity: Antipsychotic Profile of Iloperidone No. 7, pp. 1119-1131, 1995 SUBRAMANIAN, N. et al., "Receptor profile of P88-8991 and P95-iloperidone," Progress in Neuro-Psychopharmacology & Biological GUBRAMANIAN, N. et al., "Receptor profile of P88-8991 and P95-iloperidone," Progress in Neuro-Psychopharmacology & Biological COREY E. J. et al., "A Stable and Easily Prepared Catalyst for the Applications to Multistep Syntheses", Journal of the American Che 1987 MUTLIB, A.E. et al., "Application of Liquid Chromatography/Mass Experimental Theraputics, Vol. 286, No. 3 pp. 1285-1293. MUTLIB, A.E. et al., "Picogram determination of iloperidone in hun performance liquid chromatography-selected-ion monitoring electric Chromatography B. 669, 1995, pp. 237-246 | A 1997-11-11 Hoechst-Marion-Roussel Pharma h to add additional Foreign Patent Document citation information please click the Add buttor NON-PATENT LITERATURE DOCUMENTS Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when approp (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-is publisher, city and/or country where published. STRUPCZEWSKI, J.T. et al. "3-(Arylozy) Alkylpiperidinyl-1,2-Benziosoxazoles as D2/5-HT2 A Alypical Antipsychotic Activity: Antipsychotic Profile of Iloperidone (HP 873), Journal of Medici No. 7, pp. 1119-1131, 1995 2 SUBRAMANIAN, N. et al., "Receptor profile of P88-8991 and P95-12113, metabolites of the relioperidone," Progress in Neuro-Psychopharmacology & Biological Psychiatry, 26:553-560, 20 3 64 USPQ2d 1032 DECIDED 8/2002 4 COREY E. J. et al., "A Stable and Easily Prepared Catalyst for the Enanticselective Reduction Applications to Multistep Syntheses", Journal of the American Chemical Society, Vol. 109, No 1987 5 MUTLIB, A.E. et al., "Application of Liquid Chromatography/Mass Spectrometry in Acceleratin Human Liver Cytochrome P450 Isoforms Involved in the Metabolism of Iloperidone", The Jour Experimental Theraputics, Vol. 286, No. 3 pp. 1285-1293. MUTLIB, A.E. et al., "Picogram determination of iloperidone in human plasma by solid-phase performance liquid chromatography-selected-ion monitoring electrospray mass spectrometry" Chromatography B. 669, 1995, pp. 237-246 | h to add additional Foreign Patent Document citation information please click the Add button NON-PATENT LITERATURE DOCUMENTS Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. STRUPCZEWSKI, J.T. et al. "3-(Arylozy) Alkylpiperidinyl-1,2-Benziosoxazoles as D2/5-HT2 Antagonists with Potential Akypical Antipsychotic Activity. Antipsychotic Profile of lioperidone (HP 873), Journal of Medicinal Chemistry, Vol. 38, No. 7, pp. 1119-1131, 1995 SUBRAMANIAN, N. et al., "Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic lioperidone," Progress in Neuro-Psychopharmacology & Biological Psychiatry, 26:553-560, 2002 GOREY E. J. et al., "A Stable and Easily Prepared Catalyst for the Enantioselective Reduction of Ketones. Applications to Multistep Syntheses", Journal of the American Chemical Society, Vol. 109, No. 25, pp. 7925-7926, 1987 MUTLIB, A.E. et al., "Application of Liquid Chromatography/Mass Spectrometry in Accelerating the Identification of Human Liver Cytochrome P450 Isoforms Involved in the Metabolism of Iloperidone", The Journal of Pharmacology and Experimental Theraputics, Vol. 286, No. 3 pp. 1285-1293. MUTLIB, A.E. et al., "Picogram determination of iloperidone in human plasma by solid-phase extraction and by high-performance liquid chromatography-selected-ion monitoring electrospray mass spectrometry", Journal of Chromatography B. 669, 1995, pp. 237-246 |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

| Application Number | | 10575040 | | |
|----------------------------|------|--------------|--|--|
| Filing Date | | 2006-12-06 | | |
| First Named Inventor Nozul | | ak et al. | | |
| Art Unit | | 1625 | | |
| Examiner Name | Chan | g, Celia C. | | |
| Attorney Docket Number | | VAND-0030-US | | |

| 8 | WILLIAMS et al., "Importance of Drug Enantiomers in Clinical Pharmacology", Department of Clinical Pharmacology, St. Vincent's Hospital, Darlinghurst, Sydney, Drugs 30, 1985, pp 333-354 | |
|----|---|--|
| 9 | KUNTZELMANN, "Functional characterization of the enantiomers of P88-8991 at the human a2c adrenoceptor and the human dopamine D2A receptor", Novartis Pharma AG report, September 27, 2001, 8 pages | |
| 10 | NEUMANN, "The effect of the enantiomers of P88-8991 in ilperidone on spontaneous locomotion and amphetamine-induced locomotion in rats" Novartis Pharma AG report, September 27, 2001, 10 pages | |
| 11 | FURA, ABERRA, "Role of pharmacologically active metabolites in drug discovery and development", Drug Discovery Today, February 2006, 11(3/4): 133-142 | |
| 12 | CLARKE, FRANK H., "Role of Drug Metabolism in Drug Research and Development: View of a Medicinal Chemist", Journal of Pharmaceutical Sciences, 1678 | |
| 13 | BLUMER et al., "NVP-AES059-NX1 AND NVP-AES060-NX-1; Enantiomers of the P88 8991 metabolite of lloperidone: Receptor Affinity Profile (Short List)", Novartis Pharma AG report, January 28, 2001, 10 pages | |
| 14 | GRIMLER et al., Serial Number 10/488,128, 4-32076A, Office Action Communication, March 16, 2006, 8 pages. | |
| 15 | GRIMLER et al., Serial Number 10/488,128, 4-32076A, Office Action Communication, September 25, 2006, 7 pages | |
| 16 | GRIMLER et al., Serial Number 10/488,128, 4-32076A, Office Action Communication, June 14, 2007, 8 pages. | |
| 17 | GRIMLER et al., Serial Number 10/488,128, 4-32076A, Office Action Communication, March 6, 2008, 9 pages | |
| 18 | GRIMLER et al., Serial Number 10/488,128, 4-32076A, Office Action Communication, October 17, 2008, 13 pages | |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

| Application Number | | 10575040 | | |
|----------------------------|--|--------------|--|--|
| Filing Date | | 2006-12-06 | | |
| First Named Inventor Nozul | | ak et al. | | |
| Art Unit | | 1625 | | |
| Examiner Name Chang | | g, Celia C. | | |
| Attorney Docket Number | | VAND-0030-US | | |

| | 19 | GRIMLER et al, Serial Number 60/316,390, PV Application, August 31, 2001. | | | | | | |
|--|---|--|--|--|--|--|--|--|
| | 20 | GRIMLER et al., Serial Number 12/403,755 filed 03/13/2009, Attorney Docket No. VAND-0020-CON, Office Communication dated 05/05/2010, 12 pages. | | | | | | |
| | 21 | IMAMURA et al., "Interactions of pharmaceuticals with serum proteins", 1985, 1 page, CA 102:214444. | | | | | | |
| | 22 | OOKAWA et al., "Antitumor complexes and screening method thereof", 1994, 1 page, CA 120:62270. | | | | | | |
| If you wis | If you wish to add additional non-patent literature document citation information please click the Add button | | | | | | | |
| EXAMINER SIGNATURE | | | | | | | | |
| Examiner | Signa | ure Date Considered | | | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | |
| ¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. | | | | | | | | |